comparemela.com
Home
Live Updates
Scientific Session Oral Presentations - Breaking News
Pages:
Latest Breaking News On - Scientific session oral presentations - Page 1 : comparemela.com
PreludeDx™ to Present DCISionRT® and Novel Residual Risk Subtype Study Results During Scientific Oral Session at ASBrS 2022 Annual Meeting
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that.
United states
Pat whitworth
G bruce mann
Andrew wade
Cory dunn
Frank vicini
Prnewswire prelude corporation preludedx
National cancer institute
Nashville breast center
American society of breast surgeons asbr
Prelude corporation
University of california san francisco
Residual risk subtype
American society
Breast surgeons
Scientific session oral presentations
vimarsana © 2020. All Rights Reserved.